Coherus BioSciences (CHRS) News Today → Amazon's betting big on this unknown AI company (From Manward Press) (Ad) Free CHRS Stock Alerts $2.18 +0.10 (+4.81%) (As of 05/15/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 16 at 3:30 AM | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Spero Therapeutics (SPRO) and Coherus Biosciences (CHRS)May 15 at 4:01 AM | americanbankingnews.comCoherus BioSciences (NASDAQ:CHRS) Given New $7.00 Price Target at Truist FinancialMay 14 at 9:25 AM | markets.businessinsider.comCoherus Biosciences: Strong Oncology Focus and Strategic Financial Moves Justify Outperform RatingMay 13 at 6:46 AM | americanbankingnews.comHC Wainwright Raises Coherus BioSciences (NASDAQ:CHRS) Price Target to $12.00May 12, 2024 | finance.yahoo.comCoherus BioSciences, Inc. (CHRS)May 11, 2024 | finance.yahoo.comCoherus BioSciences First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 10, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Announces Earnings ResultsCoherus BioSciences (NASDAQ:CHRS - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.33). The firm had revenue of $77.06 million for the quarter, compared to analyst estimates of $102.00 million. During the same period in the previous year, the company earned ($0.89) EPS.May 10, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Price Target Raised to $12.00 at HC WainwrightHC Wainwright boosted their target price on shares of Coherus BioSciences from $11.00 to $12.00 and gave the company a "buy" rating in a research report on Friday.May 10, 2024 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comCoherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comCoherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | globenewswire.comCoherus Announces Full Repayment of Pharmakon Advisors $75 Million Term LoanMay 8, 2024 | finance.yahoo.comWhen Can We Expect A Profit From Coherus BioSciences, Inc. (NASDAQ:CHRS)?May 8, 2024 | globenewswire.comCoherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian CancerMay 8, 2024 | americanbankingnews.comCoherus BioSciences (CHRS) Set to Announce Quarterly Earnings on ThursdayMay 6, 2024 | americanbankingnews.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of "Moderate Buy" by AnalystsMay 2, 2024 | marketbeat.comCoherus BioSciences (CHRS) to Release Earnings on ThursdayCoherus BioSciences (NASDAQ:CHRS) will be releasing earnings after the market closes on Thursday, May 9, Zacks reports.May 1, 2024 | globenewswire.comCoherus to Report First Quarter 2024 Financial Results on May 9, 2024April 24, 2024 | globenewswire.comCoherus Announces Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingApril 15, 2024 | marketbeat.comShort Interest in Coherus BioSciences, Inc. (NASDAQ:CHRS) Declines By 9.5%Coherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) saw a significant drop in short interest in the month of March. As of March 31st, there was short interest totalling 23,450,000 shares, a drop of 9.5% from the March 15th total of 25,910,000 shares. Based on an average trading volume of 3,790,000 shares, the days-to-cover ratio is presently 6.2 days.April 11, 2024 | finance.yahoo.comInvestors in Coherus BioSciences (NASDAQ:CHRS) have unfortunately lost 83% over the last five yearsApril 11, 2024 | marketbeat.comVanguard Group Inc. Purchases 932,476 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)Vanguard Group Inc. lifted its position in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 10.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 9,782,127 shares of the biotechnology company's stock after acquiring an additional 9April 11, 2024 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Given Average Recommendation of "Moderate Buy" by BrokeragesCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) has earned an average rating of "Moderate Buy" from the six analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and five have assigned a buyApril 8, 2024 | finanznachrichten.deCoherus BioSciences, Inc.: Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingApril 8, 2024 | globenewswire.comCoherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual MeetingApril 2, 2024 | marketbeat.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Short Interest Up 7.1% in MarchCoherus BioSciences, Inc. (NASDAQ:CHRS - Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 25,910,000 shares, an increase of 7.1% from the February 29th total of 24,200,000 shares. Based on an average trading volume of 5,770,000 shares, the days-to-cover ratio is presently 4.5 days.March 21, 2024 | seekingalpha.comCoherus Biosciences: Dumping One Drug But Showing Promise With AnotherMarch 20, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) PT Lowered to $11.00HC Wainwright lowered their price target on Coherus BioSciences from $13.00 to $11.00 and set a "buy" rating on the stock in a research note on Wednesday.March 18, 2024 | marketbeat.comCoherus BioSciences (NASDAQ:CHRS) Earns "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $13.00 price target on shares of Coherus BioSciences in a research note on Thursday.March 16, 2024 | finance.yahoo.comCoherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)March 15, 2024 | markets.businessinsider.comCoherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform RatingMarch 15, 2024 | finance.yahoo.comCoherus BioSciences Full Year 2023 Earnings: EPS Misses ExpectationsMarch 14, 2024 | fool.comWhy Coherus Biosciences Stock Tumbled on ThursdayMarch 14, 2024 | seekingalpha.comCoherus BioSciences, Inc. (CHRS) Q4 2023 Earnings Call TranscriptMarch 14, 2024 | finance.yahoo.comQ4 2023 Coherus BioSciences Inc Earnings CallMarch 13, 2024 | benzinga.comRecap: Coherus BioSciences Q4 EarningsMarch 13, 2024 | markets.businessinsider.comCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateMarch 13, 2024 | msn.comCoherus BioSciences Non-GAAP EPS of -$0.62 misses by $0.52, revenue of $91.5M beats by $1.07MMarch 13, 2024 | finance.yahoo.comCoherus BioSciences Inc (CHRS) Reports Growth in Net Revenue for Q4 and Full Year 2023 Despite ...March 13, 2024 | globenewswire.comCoherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business UpdateMarch 12, 2024 | msn.comCoherus BioSciences Q4 2023 Earnings PreviewMarch 6, 2024 | finance.yahoo.comIn the wake of Coherus BioSciences, Inc.'s (NASDAQ:CHRS) latest US$49m market cap drop, institutional owners may be forced to take severe actionsMarch 6, 2024 | marketbeat.comCoherus BioSciences (CHRS) to Release Quarterly Earnings on WednesdayCoherus BioSciences (NASDAQ:CHRS) will be releasing earnings after the market closes on Wednesday, March 13, Zacks reports.March 5, 2024 | globenewswire.comCoherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024March 4, 2024 | finanznachrichten.deCoherus BioSciences, Inc.: Coherus Completes Divestiture of Ophthalmology FranchiseMarch 4, 2024 | globenewswire.comCoherus Completes Divestiture of Ophthalmology FranchiseMarch 3, 2024 | marketbeat.comCoherus BioSciences (CHRS) Set to Announce Quarterly Earnings on MondayCoherus BioSciences (NASDAQ:CHRS) will be releasing earnings on Monday, March 4, Yahoo Finance reports.February 25, 2024 | marketbeat.comBrandywine Global Investment Management LLC Boosts Stake in Coherus BioSciences, Inc. (NASDAQ:CHRS)Brandywine Global Investment Management LLC lifted its holdings in Coherus BioSciences, Inc. (NASDAQ:CHRS - Free Report) by 64.7% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 666,245 shares of the biotechnology company's stock after pFebruary 23, 2024 | globenewswire.comCoherus BioSciences Announces New Employment Inducement Grants Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Top 5 AI Stocks to Buy for 2024 (Ad)5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist. Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In" CHRS Media Mentions By Week CHRS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CHRS News Sentiment▼0.190.55▲Average Medical News Sentiment CHRS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CHRS Articles This Week▼174▲CHRS Articles Average Week Get Coherus BioSciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Fennec Pharmaceuticals News Sutro Biopharma News Agenus News Metagenomi News Adaptimmune Therapeutics News Compass Therapeutics News Candel Therapeutics News Poseida Therapeutics News Monte Rosa Therapeutics News Century Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CHRS) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Coherus BioSciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
